Literature DB >> 16556244

Does earlier headache response equate to earlier return to functioning in patients suffering from migraine?

F G Pradel1, P Subedi, A A Varghese, C D Mullins, K A Weis.   

Abstract

This study explored the association between headache response and return to functioning, and identified migraine-associated symptoms related to functional status and acceptability of migraine treatment as reported by patients. Data from migraineurs enrolled in the active arms of a randomized, double-blind, parallel group, placebo-controlled, clinical trial were analysed. The relationships between headache response and functional response, and clinical factors and treatment acceptability were assessed using chi(2) tests of proportions and logistic regressions. A greater proportion of patients with headache response at 0.5 h were functioning at 0.5, 1 and 2 h compared with patients who did not attain a headache response at 0.5 h (P < 0.0001). These patients also were more likely to find their treatment acceptable (P < 0.05). The results suggest a direct temporal relationship among the key determinants of migraine resolution. Rapid headache response is associated with faster return to functioning; rapid headache and functional responses are significant attributes of treatment acceptability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556244     DOI: 10.1111/j.1468-2982.2005.01043.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  3 in total

Review 1.  Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults.

Authors:  Christopher J Derry; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 2.  Sumatriptan (oral route of administration) for acute migraine attacks in adults.

Authors:  Christopher J Derry; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

3.  Current migraine management - patient acceptability and future approaches.

Authors:  Arnaud Fumal; Jean Schoenen
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.